A pain in the ear: What has the 7-valent conjugated pneumococcal vaccine done to reduce the incidence of acute otitis media?

Clinical Infectious Diseases

Volumn 40, Issue 12, 2005, Pages 1745-1747

  Regelmann, Warren E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; HEPATITIS B VACCINE; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ACUTE DISEASE; BACTERIUM CULTURE; CHILD; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; OTALGIA; OTITIS MEDIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ACUTE DISEASE; HUMANS; INCIDENCE; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 20444428730     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429925     Document Type: Note

References (14)

1. Carlin SA, Marchant CD, Shurin PA, Johnson CE, Super DM, Rehmus JM. Host factors and early therapeutic response in acute otitis media. J Pediatr 1991; 118:178-83.
2. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother 1998; 42:589-95.
3. Hausdorff WP, Yothers G, Dagan R, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 2002; 21:1008-16.
4. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
5. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9.
6. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004; 23:1142-52.
7. Harrison CJ. Changes in treatment strategies for acute otitis media after full implementation of the pneumococcal seven valent conjugate vaccine. Pediatr Infect Dis J 2003; 22:S120-30.
8. McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumon iae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2005; 40:1738-44 (in this issue).
9. Dhooge IJ, van Kempen MJ, Sanders LA, Rijkers GT. Deficient IgA and IgG2 anti-pneumococcal antibody levels and response to vaccination in otitis prone children. Int J Pediatr Otorhinolaryngol 2002;64:133-41.
10. Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 2004; 190:545-50.
11. Nurkka A, Ahman H, Korkeila M, Jantti V, Kayhty H, Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20:25-33.
12. Block SL, Hedrick J, Harrison CJ, et al. Pneumococcal serotypes from acute otitis media in rural Kentucky. Pediatr Infect Dis J 2002; 21:859-65.
13. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004; 22:2209-20.
14. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149:1113-7.